SecBot SecBot
6-K ·Filed Sep 14, 2026

GSK

GSK plc
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001654954-26-008321
Notable filing: 6-K
Actionable Insight ▲ Bullish

This is a strong clinical catalyst for GSK's oncology pipeline. The magnitude of OS benefit (54% risk reduction, 8.2-month median gain) and first-in-class B7-H3 ADC data de-risk the broader Ris-Rez program. Watch for the EMBOLD SCLC-301 pivotal readout next year and potential regulatory filings outside China. The stock may re-rate on pipeline optionality.

DirectionBullish
Confidencehigh
Horizonweeks

Drug in focus

GSK drug pipeline →

risvutatug rezetecan

▲ Bullish Named in this 6-K
Impact
Phase
Phase 3
Time to market
~3-4 years for global approval; China approval possible ~12-18 months post Hansoh filing
Next catalyst
None dated

What to watchThe ARTEMIS-008 Phase 3 win in China (positive OS vs topotecan in SCLC) is a major validation of the B7-H3 ADC mechanism, but for GSK investors the real catalyst is the global Phase 3 readout (primary completion now Oct 2027). Watch for China NDA filing timing and any early data from the ongoing EMBOLD/ARTEMIS expansion trials in prostate, NSCLC, and other solid tumors. With ~$1-2B peak sales potential (ex-China), risvutatug rezetecan is a meaningful but non-binary asset within GSK's broader pipeline.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$50.05
T+0 close · Sep 14, 2026 · via day close
Latest settled
−6.25%
T+20 · $46.92 · next T+60 in 21d
Vs SPY
−8.52%
α at T+20
Latest observation
+3.50%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $50.05entry
  2. T+1 · 2mo ago −0.08%α +0.38% · $50.01
  3. T+5 · 8w ago +2.06%α +1.95% · $51.08
  4. T+20 · 5w ago −6.25%α −8.52% · $46.92
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK announced positive overall survival data from the ARTEMIS-008 Phase III trial of Ris-Rez (risvutatug rezetecan) in relapsed small cell lung cancer in China. Ris-Rez reduced the risk of death by 54% vs topotecan (HR 0.46, p<0.0001), with median OS of 18.5 months vs 10.3 months, and showed a favorable safety profile. This is the first Phase III data to demonstrate an OS benefit for a B7-H3 ADC in any tumor type, supporting GSK's global development program with pivotal data from the EMBOLD SCLC-301 trial expected next year.

Key Facts

  • Ris-Rez reduced risk of death by 54% vs topotecan in relapsed SCLC (HR 0.46; 95% CI: 0.35-0.62, p<0.0001)
  • Median OS: 18.5 months (Ris-Rez) vs 10.3 months (topotecan)
  • Median PFS: 7.2 months vs 3.0 months (HR 0.33)
  • Objective response rate: 58.3% vs 12.6%
  • Grade 3+ TRAEs: 60.9% (Ris-Rez) vs 78.2% (topotecan)
  • First Phase III data to show OS benefit for a B7-H3 ADC in any tumor type
  • GSK holds ex-China rights; pivotal global data from EMBOLD SCLC-301 expected next year

Financial Impact

Positive Phase III OS data for Ris-Rez in SCLC, a high-unmet-need indication; potential peak sales could be significant but no revenue figures provided in filing

pipeline valueR&D sentimentfuture revenue potential

Risk Factors

  • Data are from a China-only trial; global regulatory path and commercial uptake outside China are unproven
  • Competitive landscape for B7-H3 ADCs is evolving with multiple developers
  • Pivotal global data from EMBOLD SCLC-301 not yet available; execution risk remains

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-008321
Document: 0001654954-26-008321-index-headers.html0001654954-26-008321
Document: 0001654954-26-008321-index.html0001654954-26-008321
Document: 0001654954-26-008321.txt0001654954-26-008321

US Market Status

Market Closed · Opens Wed (11h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026